FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2592691282> ?p ?o ?g. }

• W2592691282 endingPage "605" @default.
• W2592691282 startingPage "597" @default.
• W2592691282 abstract "Background: Although superior clinical benefits of first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer (NSCLC) had been reported with different sensitivity, the sensitivity of second-line TKIs in NSCLC patients with different EFGR mutations was unknown. The purpose of this study is to investigate the clinical outcome of second-line EGFR-TKIs in the treatment of NSCLC patients according to different EGFR genotypes. Methods: The treatment outcomes of 166 NSCLC patients with different EGFR mutations treated by second-line TKIs were retrospectively reviewed. The efficacy was evaluated with Pearson chi-square or Fisher's exact tests, Log-rank test and Cox proportional hazards model. Results: The disease control rate (DCR) and objective response rate (ORR) of enrolled NSCLC patients were 77.7% and 11.4%, respectively. The exon 19 deletion group had a significantly longer median progression-free survival (PFS) (6.7 vs. 4.5 months, P=0.002) and overall survival (OS) (13.7 vs. 11.7 months, P=0.02) compared with the exon 19 L858R mutation group for NSCLC patients, as well for patients with brain metastasis [PFS: (6.7 vs. 3.9 months, p<0.001), OS: (13.7 vs. 7.9 months, p=0.006)]. No significant difference on PFS and OS was observed between exon 19 deletion and L858R mutation group for patients with bone metastasis. EGFR genotype and ECOG PS were independent predictors of PFS. Never smoking, exon 19 deletion, EGOC PS (0-1) and no brain metastasis were correlated with longer OS. No significant difference on side effect between exon 19 and 21 mutation group was observed. Conclusions: NSCLC patients harboring exon 19 deletion achieved better PFS and OS than those with L858R mutation, indicating that EGFR mutation is a significant prognostic factor for advanced NSCLC patients with and without brain metastasis receiving second-line EGFR-TKIs treatment." @default.
• W2592691282 created "2017-03-16" @default.
• W2592691282 creator A5010912456 @default.
• W2592691282 creator A5024853481 @default.
• W2592691282 creator A5026906686 @default.
• W2592691282 creator A5028098930 @default.
• W2592691282 creator A5033482016 @default.
• W2592691282 creator A5037147271 @default.
• W2592691282 creator A5040425007 @default.
• W2592691282 creator A5059536413 @default.
• W2592691282 creator A5087648864 @default.
• W2592691282 creator A5090325393 @default.
• W2592691282 date "2017-01-01" @default.
• W2592691282 modified "2023-09-27" @default.
• W2592691282 title "Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations" @default.
• W2592691282 cites W1533573067 @default.
• W2592691282 cites W1554896841 @default.
• W2592691282 cites W1976972366 @default.
• W2592691282 cites W1983487853 @default.
• W2592691282 cites W1996589664 @default.
• W2592691282 cites W1999896690 @default.
• W2592691282 cites W2007528734 @default.
• W2592691282 cites W2015068550 @default.
• W2592691282 cites W2018508449 @default.
• W2592691282 cites W2023816433 @default.
• W2592691282 cites W2048733384 @default.
• W2592691282 cites W2049805045 @default.
• W2592691282 cites W2056686211 @default.
• W2592691282 cites W2058621664 @default.
• W2592691282 cites W2064362213 @default.
• W2592691282 cites W2087504862 @default.
• W2592691282 cites W2087769940 @default.
• W2592691282 cites W2089263234 @default.
• W2592691282 cites W2094771796 @default.
• W2592691282 cites W2095618958 @default.
• W2592691282 cites W2096065464 @default.
• W2592691282 cites W2096786080 @default.
• W2592691282 cites W2104748005 @default.
• W2592691282 cites W2108882588 @default.
• W2592691282 cites W2113465576 @default.
• W2592691282 cites W2114464493 @default.
• W2592691282 cites W2114472079 @default.
• W2592691282 cites W2118922921 @default.
• W2592691282 cites W2121641332 @default.
• W2592691282 cites W2124569973 @default.
• W2592691282 cites W2129360604 @default.
• W2592691282 cites W2130254323 @default.
• W2592691282 cites W2131664752 @default.
• W2592691282 cites W2132157071 @default.
• W2592691282 cites W2132870547 @default.
• W2592691282 cites W2138297714 @default.
• W2592691282 cites W2147840374 @default.
• W2592691282 cites W2150485455 @default.
• W2592691282 cites W2151076549 @default.
• W2592691282 cites W2153477391 @default.
• W2592691282 cites W2153942353 @default.
• W2592691282 cites W2153979476 @default.
• W2592691282 cites W2154130790 @default.
• W2592691282 cites W2168161641 @default.
• W2592691282 cites W2168856723 @default.
• W2592691282 cites W359524515 @default.
• W2592691282 cites W656206267 @default.
• W2592691282 doi "https://doi.org/10.7150/jca.16959" @default.
• W2592691282 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5370503" @default.
• W2592691282 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28367239" @default.
• W2592691282 hasPublicationYear "2017" @default.
• W2592691282 type Work @default.
• W2592691282 sameAs 2592691282 @default.
• W2592691282 citedByCount "6" @default.
• W2592691282 countsByYear W25926912822017 @default.
• W2592691282 countsByYear W25926912822018 @default.
• W2592691282 countsByYear W25926912822019 @default.
• W2592691282 countsByYear W25926912822023 @default.
• W2592691282 crossrefType "journal-article" @default.
• W2592691282 hasAuthorship W2592691282A5010912456 @default.
• W2592691282 hasAuthorship W2592691282A5024853481 @default.
• W2592691282 hasAuthorship W2592691282A5026906686 @default.
• W2592691282 hasAuthorship W2592691282A5028098930 @default.
• W2592691282 hasAuthorship W2592691282A5033482016 @default.
• W2592691282 hasAuthorship W2592691282A5037147271 @default.
• W2592691282 hasAuthorship W2592691282A5040425007 @default.
• W2592691282 hasAuthorship W2592691282A5059536413 @default.
• W2592691282 hasAuthorship W2592691282A5087648864 @default.
• W2592691282 hasAuthorship W2592691282A5090325393 @default.
• W2592691282 hasBestOaLocation W25926912821 @default.
• W2592691282 hasConcept C104317684 @default.
• W2592691282 hasConcept C121608353 @default.
• W2592691282 hasConcept C126322002 @default.
• W2592691282 hasConcept C143998085 @default.
• W2592691282 hasConcept C170493617 @default.
• W2592691282 hasConcept C191093355 @default.
• W2592691282 hasConcept C2776256026 @default.
• W2592691282 hasConcept C2776694085 @default.
• W2592691282 hasConcept C2778820342 @default.
• W2592691282 hasConcept C2779013556 @default.
• W2592691282 hasConcept C2779438470 @default.
• W2592691282 hasConcept C2780739268 @default.
• W2592691282 hasConcept C36823959 @default.

• next